Choueiri, Toni K.

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 5,870

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 5,807

Post-acute COVID-19 syndrome

Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine

Long-Term Effects of COVID-19COVID-19 Clinical Research Studies

Cited by 4,862

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 4,656

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 3,395

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,791

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,260

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersChromatin Remodeling and Cancer

Cited by 1,249

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., et al. (2020) · Nature Medicine

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 992

A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis

Zou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y.-Y., Deasy, R., Kost-Alimova, M., Dančík, V., et al. (2019) · Nature Communications

Ferroptosis and cancer prognosisCancer, Hypoxia, and Metabolism

Cited by 887

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., et al. (2019) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 775

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell

PI3K/AKT/mTOR signaling in cancerCancer Genomics and Diagnostics

Cited by 626

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 620

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., et al. (2020) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 518

Targeting the HIF2–VEGF axis in renal cell carcinoma

Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 477

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 393

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 356

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Fong, L., Hotson, A., Powderly, J. D., Sznol, M., Heist, R. S., Choueiri, T. K., George, S., Hughes, B. G. M., Hellmann, M. D., Shepard, D. R., et al. (2020) · Cancer Discovery

Adenosine and Purinergic SignalingCancer Immunotherapy and Biomarkers

Cited by 352

Landscape of tumor-infiltrating T cell repertoire of human cancers

Li, B., Li, T., Pignon, J.-C., Wang, B., Wang, J., Shukla, S. A., Dou, R., Chen, Q., Hodi, F. S., Choueiri, T. K., et al. (2016) · Nature Genetics

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 306

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 305

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., Stadler, W. M., Perez-Gracia, J. L., McNeel, D. G., Curti, B., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 295

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 287

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial

Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 260